- Home
- POWI vs ETNB Comparison
POWI vs ETNB Comparison
Compare POWI & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POWI
- ETNB
- Stock Information
- Founded
- POWI 1988
- ETNB 2018
- Country
- POWI United States
- ETNB United States
- Employees
- POWI N/A
- ETNB 93
- Industry
- POWI Semiconductors
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- POWI Technology
- ETNB Health Care
- Exchange
- POWI Nasdaq
- ETNB Nasdaq
- Market Cap
- POWI 2.3B
- ETNB 2.2B
- IPO Year
- POWI 1997
- ETNB 2019
- Fundamental
- Price
- POWI $37.67
- ETNB $14.83
- Analyst Decision
- POWI Strong Buy
- ETNB Buy
- Analyst Count
- POWI 3
- ETNB 10
- Target Price
- POWI $61.67
- ETNB $22.31
- AVG Volume (30 Days)
- POWI 698.6K
- ETNB 9.5M
- Earning Date
- POWI 11-05-2025
- ETNB 11-06-2025
- Dividend Yield
- POWI 2.23%
- ETNB N/A
- EPS Growth
- POWI N/A
- ETNB N/A
- EPS
- POWI 0.59
- ETNB N/A
- Revenue
- POWI $442,468,000.00
- ETNB N/A
- Revenue This Year
- POWI $11.06
- ETNB N/A
- Revenue Next Year
- POWI $14.36
- ETNB N/A
- P/E Ratio
- POWI $63.85
- ETNB N/A
- Revenue Growth
- POWI 7.16
- ETNB N/A
- 52 Week Low
- POWI $37.62
- ETNB $4.16
- 52 Week High
- POWI $69.53
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- POWI 29.03
- ETNB 79.17
- Support Level
- POWI $38.59
- ETNB $14.67
- Resistance Level
- POWI $39.78
- ETNB $14.93
- Average True Range (ATR)
- POWI 1.34
- ETNB 0.09
- MACD
- POWI -0.17
- ETNB 0.06
- Stochastic Oscillator
- POWI 0.65
- ETNB 41.03
About POWI Power Integrations Inc.
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).